Literature DB >> 29718792

A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?"

Justin E Bekelman1.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 61-year-old man presents with stage II prostate cancer after a period of active surveillance. Work-up reveals T1cN0M0 carcinoma, a prostate-specific antigen (PSA) level of 4.8 ng/mL, and Grade Group II (highest Gleason 3+4) in three cores of 12 taken, at the right mid-gland and right apex. The patient has been on active surveillance for the past 16 months. He was originally diagnosed after biopsy for an elevated PSA with stage I prostate cancer, T1cN0M0; PSA, 4.5 ng/mL; Grade Group 1 (Gleason 3+3) in one core of 12 taken, also at the right mid-gland. A multiparametric magnetic resonance imaging scan showed a heterogeneous peripheral zone without a dominant lesion and a calculated prostate volume of 28 mL. His medical history includes hypercholesterolemia, for which he takes atorvastatin. He is otherwise healthy and has no other significant medical or surgical history. His father had prostate cancer in his 70s and died of other causes at 89 years of age. The patient reports 2- to 3-hour urinary frequency and 0 to 1 nocturia, and has no difficulty obtaining or maintaining an erection. After meeting with his urologist, he sees a radiation oncologist.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29718792      PMCID: PMC6008106          DOI: 10.1200/JCO.2018.77.7235

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.

Authors:  Amy Berrington de Gonzalez; Jeannette Wong; Ruth Kleinerman; Clara Kim; Lindsay Morton; Justin E Bekelman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

2.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.

Authors:  D J Brenner; R E Curtis; E J Hall; E Ron
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.

Authors:  Bradford S Hoppe; Jeff M Michalski; Nancy P Mendenhall; Christopher G Morris; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Christopher R Williams; Meredith M Regan; Jonathan J Chipman; Catrina M Crociani; Howard M Sandler; Martin G Sanda; Daniel A Hamstra
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

4.  Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study.

Authors:  R Mathieu; M Moschini; B Beyer; K M Gust; T Seisen; A Briganti; P Karakiewicz; C Seitz; L Salomon; A de la Taille; M Rouprêt; M Graefen; S F Shariat
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-10       Impact factor: 5.554

5.  Late gastrointestinal toxicities following radiation therapy for prostate cancer.

Authors:  Sung Kim; Shunhua Shen; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Matthew Dolan; Yu-Hsuan Shao; Grace L Lu-Yao
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

6.  Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.

Authors:  Hubert Y Pan; Jing Jiang; Karen E Hoffman; Chad Tang; Seungtaek L Choi; Quynh-Nhu Nguyen; Steven J Frank; Mitchell S Anscher; Ya-Chen Tina Shih; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2018-03-21       Impact factor: 44.544

7.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.

Authors:  Nathan C Sheets; Gregg H Goldin; Anne-Marie Meyer; Yang Wu; YunKyung Chang; Til Stürmer; Jordan A Holmes; Bryce B Reeve; Paul A Godley; William R Carpenter; Ronald C Chen
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

8.  ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Authors:  Brian J Davis; Al V Taira; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Timothy N Showalter; Neha Vapiwala
Journal:  Brachytherapy       Date:  2016-12-07       Impact factor: 2.362

9.  Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.

Authors:  Joshua A Halpern; Art Sedrakyan; Wei-Chun Hsu; Jialin Mao; Timothy J Daskivich; Paul L Nguyen; Encouse B Golden; Josephine Kang; Jim C Hu
Journal:  Cancer       Date:  2016-05-25       Impact factor: 6.860

10.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Authors:  W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

View more
  1 in total

1.  Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.

Authors:  Julie Nossiter; Arunan Sujenthiran; Thomas E Cowling; Matthew G Parry; Susan C Charman; Paul Cathcart; Noel W Clarke; Heather Payne; Jan van der Meulen; Ajay Aggarwal
Journal:  J Clin Oncol       Date:  2020-01-02       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.